SetPoint Medical appoints senior regulatory execs as it advances neuromodulation clinical trials.
SetPoint Medical Corp. has expanded its senior management team, promoting Lusin Markaryan to the role of vice president, regulatory affairs, and appointing Raju Joshi as vice president, clinical affairs.
Markaryan was previously SetPoint's senior director, regulatory affairs. Prior to that, she served as director, regulatory affairs for Medtronic PLC 's non-intensive diabetes therapies business. Joshi joins SetPoint from...
Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.
After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.
